About
Mulberry Biotherapeutics develops bacteria-mediated immunotherapies for rare, slow-growing tumors such as Neurofibromatosis type 2-related schwannomatosis by using live, genetically engineered bacteria to stimulate immune responses and tumor reduction.
Explore Mulberry Biotherapeutics's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.